High Performance Antigen Diagnostics
- Notice type
- Sources Sought
- Product or service code
- AN13 · HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- Set-aside
- Not specified
- Place of performance
- District of ColumbiaWashington, DC
- Official notice
- View on SAM.gov ↗
Description
“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.
The rest of this notice
The buyer's named contact and the award details for this notice are free. Create an account to open the full record.
- Contact the buyer directly
- See who won, and for how much
- Get alerts for opportunities like this one
Free — no card, no trial clock.